NCT07090889View on ClinicalTrials.gov

Study of KM-023 in Healthy Volunteers and Patients With Olmsted Syndrome.

PHASE1RecruitingINTERVENTIONAL

Enrollment

64

Participants

Timeline

Start Date

July 8, 2025

Primary Completion Date

February 11, 2026

Study Completion Date

February 11, 2026

Conditions

Olmsted Syndrome

Interventions

DRUG

KM-023

solution for oral administration

DRUG

Placebo

solution for oral administration

Trial Locations (1)

Unknown

RECRUITING

Biotrial, Rennes

Sponsors

Lead Sponsor

Kamari Pharma Ltd

All Listed Sponsors

lead

Kamari Pharma Ltd

NETWORK

NCT07090889 - Study of KM-023 in Healthy Volunteers and Patients With Olmsted Syndrome. | Biotech Hunter | Biotech Hunter